IL37 and gestational diabetes: Furthermore, the observations that IL-37 and IL-38, anti-inflammatory cytokines, are dysregulated in the placenta during the progression of GDM and pre-eclampsia, invites speculation that IL-37 and/or IL-38 could be target(s) in preventing and/or management of these two obstetric abnormalities, eventually reducing local and/or systemic inflammation.